4//SEC Filing
ONYX PHARMACEUTICALS INC 4
Accession 0001179110-13-011352
CIK 0001012140operating
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 6:53 PM ET
Size
19.0 KB
Accession
0001179110-13-011352
Insider Transaction Report
Form 4
WOOD JULIANNA R
VP, Corp. Communication/I.R.
Transactions
- Exercise/Conversion
Common Stock
2013-07-01$30.28/sh+765$23,164→ 20,139 total - Exercise/Conversion
Stock Option (Right to Buy)
2013-07-01−765→ 5,104 totalExercise: $30.28Exp: 2020-03-31→ Common Stock (765 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2013-07-01−719→ 16,291 totalExercise: $37.68Exp: 2022-03-29→ Common Stock (719 underlying) - Exercise/Conversion
Common Stock
2013-07-01$37.68/sh+719$27,092→ 21,405 total - Sale
Common Stock
2013-07-01$132.63/sh−2,304$305,580→ 19,374 total - Exercise/Conversion
Stock Option (Right to Buy)
2013-07-01−547→ 8,021 totalExercise: $35.18Exp: 2021-03-31→ Common Stock (547 underlying) - Exercise/Conversion
Common Stock
2013-07-01$35.18/sh+547$19,243→ 20,686 total - Exercise/Conversion
Stock Option (Right to Buy)
2013-07-01−273→ 0 totalExercise: $28.55Exp: 2019-03-31→ Common Stock (273 underlying) - Exercise/Conversion
Common Stock
2013-07-01$28.55/sh+273$7,794→ 21,678 total
Holdings
- 200(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]Shares sold pursuant to a 10b5-1 plan.
- [F2]12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
- [F3]Fully vested.
Documents
Issuer
ONYX PHARMACEUTICALS INC
CIK 0001012140
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001012140
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 6:53 PM ET
- Size
- 19.0 KB